News

Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...
Canadians with Down syndrome live until 60 on average, study finds
In Canada, "the average lifespan of someone with Down syndrome is about 60 years old," said Dr. Brian Skotko, senior author of the study.
Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...